Anatol Kreitzer, the chief discovery officer of MapLight Therapeutics (MPLT +3.06%), reported the direct sale of 3,316 shares of Common Stock for a total transaction value of approximately $88,000, according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 3,316 |
| Transaction value | ~$88,000 |
| Post-transaction shares (direct) | 256,612 |
| Post-transaction value (direct ownership) | ~$6.9 million |
Transaction value based on SEC Form 4 weighted average purchase price ($26.61); post-transaction value based on April 15, 2026 market close ($26.61).
Key questions
- How material is this transaction given Kreitzer's overall stake?
The 3,316 shares sold constituted just 1% of Kreitzer's direct Common Stock holdings, leaving his ownership position largely unchanged post-sale. - Was there any indirect or derivative participation in this trade?
The transaction affected only directly held Common Stock; no indirect entities or derivative securities (such as options) were involved or reported as part of this filing. - Does this sale represent a change in trading cadence or intent?
This is Kreitzer’s first sell transaction in the recent period, and with capacity indicators showing minimal change in holdings, the activity is consistent with routine liquidity management rather than a strategic reduction. - What does Kreitzer still own after this transaction?
Kreitzer continues to hold 256,612 shares of Voting Common Stock (direct); these shares remain eligible for conversion to Common Stock, preserving a substantial insider position.
Company overview
| Metric | Value |
|---|---|
| Price (as of Wednesday) | $32.96 |
| Market capitalization | $1.5 billion |
| Net income (TTM) | -$161.15 million |
Company snapshot
- MapLight Therapeutics develops clinical-stage therapeutics targeting central nervous system disorders, with a pipeline including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, ML-004 for autism spectrum disorder, ML-021 for Parkinson's disease, and ML-009 for hyperactivity and agitation-related conditions.
- The firm operates a biopharmaceutical business model focused on discovering and advancing novel drug candidates, leveraging proprietary neural circuit identification platforms to address unmet medical needs.
- It targets patients suffering from debilitating neurological and psychiatric disorders, with primary customers expected to be healthcare providers, hospitals, and specialty clinics treating CNS conditions.
MapLight Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel therapeutics for central nervous system disorders. The company leverages a proprietary platform to identify and modulate neural circuits causally linked to disease, aiming to deliver targeted treatments for complex neurological and psychiatric conditions. With a focused pipeline and expertise in CNS drug development, MapLight Therapeutics seeks to address significant unmet needs and establish a differentiated position in the biopharmaceutical sector.
What this transaction means for investors
Shares of MapLight Therapeutics have skyrocketed about 73% over the past year, but this sale ultimately looks like routine liquidity rather than a signal of shifting conviction. The transaction represented just 1% of Kreitzer’s holdings, and the footnote makes clear that the shares were sold to cover statutory tax withholding obligations in connection with the vesting of RSUs.
What matters more is where the business stands. MapLight is still firmly in the clinical-stage bucket, but it’s entering a more catalyst-heavy stretch. The company expects Phase 2 enrollment for its lead schizophrenia program to wrap this month, with topline data in the third quarter, alongside results from its autism study. That clustering of readouts is key because it compresses multiple valuation inflection points into a relatively short window.
Financially, the company ended 2025 with $453.1 million in cash, which management says is enough to fund operations through 2027. R&D spending, meanwhile, is ramping to $138.3 million for the year, and quarterly net losses are widening to $79.5 million. With that in mind, what will matter next is whether upcoming trials validate the platform and justify the burn.
